KB-1354

ARX517-hIgG1

Home » Antibody » ARX517-hIgG1

Background

1. hen J, Pachynski R, Nordquist LT, et al. APEX-01: First-in-human phase I/II study of ARX517 an anti- prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol. 2023;34(suppl 2):S974-S975. doi:10.1016/j.annonc.2023.09.2752 2. FDA grants Fast Track Designation for Ambrx¡¯s ARX517 for the treatment of metastatic castration-resistant prostate cancer. News release. Ambrx Biopharma Inc. July 19, 2023. Accessed October 25, 2023.

Specifications

Catalog Number:
KB-1354
Cell Line Name:
ARX517-hIgG1
Price:
0
Host Cell Line:
EXPI-CHO
Target:
PSMA
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2¦Ìm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20¡ãC to -80¡ãC; Stored at 2-8¡ãC for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1. hen J, Pachynski R, Nordquist LT, et al. APEX-01: First-in-human phase I/II study of ARX517 an anti- prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol. 2023;34(suppl 2):S974-S975. doi:10.1016/j.annonc.2023.09.2752 2. FDA grants Fast Track Designation for Ambrx¡¯s ARX517 for the treatment of metastatic castration-resistant prostate cancer. News release. Ambrx Biopharma Inc. July 19, 2023. Accessed October 25, 2023.
Please enable JavaScript in your browser to complete this form.